Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
79.62
Oct 21 • 3:59 PM ET Dollar change-0.42 Percentage change(-0.52%)
Aftermarket Close
78.50
Aftermarket • 7:56 PM ET Dollar change-1.12 Percentage change(-1.41%)
Oct 20, 4:50 PMZoetis gets U.S. FDA approval for Convenia RTU for Dogs to treat bacterial skin infections, launch expected early 2027
Index
S&P 500
Market Cap
32.90B
Enterprise Value
40.46B
Income
2.62B
Sales
9.52B
Book/sh
7.60
Cash/sh
4.06
Employees
14500
IPO
Feb 01, 2013
P/E
13.10
Forward P/E
12.48
PEG
5.52
P/S
3.46
P/B
10.47
P/C
19.63
P/FCF
13.91
EV/EBITDA
9.95
EV/Sales
4.25
Quick Ratio
1.84
Current Ratio
3.08
Debt/Eq
2.93
LT Debt/Eq
2.93
Option/Short
Yes / Yes
EPS (ttm)
6.08
EPS next Y
6.38
EPS next Q
1.51
EPS this Y
-3.10%
EPS next Y
2.74%
EPS next 5Y
2.26%
EPS past 3/5Y
10.25% 11.96%
Sales past 3/5Y
5.42% 7.24%
EPS Y/Y TTM
4.54%
Sales Y/Y TTM
1.41%
EPS Q/Q
2.64%
Sales Q/Q
0.33%
Insider Own
0.23%
Insider Trans
1.24%
Inst Own
100.37%
Inst Trans
-4.00%
ROA
17.70%
ROE
64.39%
ROIC
21.12%
Gross Margin
70.22%
Oper. Margin
37.65%
Profit Margin
27.49%
SMA20
7.88%
SMA50
7.14%
SMA200
-16.33%
Trades
Shs Outstand
414.15M
Shs Float
412.28M
52W High
148.30 -46.31%
52W Low
68.77 15.78%
Volatility
2.26% 2.44%
ATR (14)
1.86
RSI (14)
68.58
Beta
0.70
Rel Volume
0.58
Avg Volume
5.21M
Volume
3,037,283
Perf Week
5.75%
Perf Month
9.28%
Perf Quarter
6.77%
Perf Half Y
-32.25%
Perf YTD
-36.72%
Perf Year
-45.50%
Perf 3Y
-52.35%
Perf 5Y
-61.83%
Perf 10Y
56.30%
Prev Close
80.04
Price
79.62
Change %
-0.52%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK ADirectorMay 13 '26Buy75.396,650501,34421,458May 13 04:35 PM
Bisaro PaulDirectorMay 13 '26Buy75.882,000151,75027,862May 13 04:35 PM
MCCALLISTER MICHAEL BDirectorMay 11 '26Buy77.763,000233,27324,524May 12 07:26 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Option Exercise41.8320,000836,600121,337Feb 17 04:22 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Sale127.0520,0002,540,964101,337Feb 17 04:22 PM
Polzer Robert JOfficerFeb 17 '26Proposed Sale127.342,346298,742Feb 17 04:14 PM
PECK KRISTIN COfficerFeb 17 '26Proposed Sale127.0520,0002,540,964Feb 17 04:13 PM
Polzer Robert JOfficerFeb 13 '26Proposed Sale129.093,662472,728Feb 13 04:26 PM
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
CEO & DirectorMs. Kristin C. Peck
Executive VPMs. Roxanne Lagano
Special Advisor to the CEOMr. Wetteny N. Joseph CPA
Scientific AdvisorDr. Robert J. Polzer Ph.D.
Executive VP & Chief Commercial OfficerMr. Jamie Brannan